更新于：2024-09-19

PPP1R8

更新于：2024-09-19

基本信息

别名

Activator of RNA decay、ard-1、ARD1

+ [7]

简介

Inhibitor subunit of the major nuclear protein phosphatase-1 (PP-1). It has RNA-binding activity but does not cleave RNA and may target PP-1 to RNA-associated substrates. May also be involved in pre-mRNA splicing. Binds DNA and might act as a transcriptional repressor. Seems to be required for cell proliferation. Isoform Gamma is a site-specific single-strand endoribonuclease that cleaves single strand RNA 3' to purines and pyrimidines in A+U-rich regions. It generates 5'-phosphate termini at the site of cleavage. This isoform does not inhibit PP-1. May be implicated in mRNA splicing.

关联

项与 PPP1R8 相关的药物

EBT-001

靶点

PPP1R8

作用机制

PPP1R8 inhibitors

在研机构

Ernest Pharmaceuticals, Lcc初创企业

原研机构

Ernest Pharmaceuticals, Lcc初创企业

在研适应症

转移性乳腺癌

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 PPP1R8 相关的临床结果

登录后查看更多信息

100 项与 PPP1R8 相关的转化医学

登录后查看更多信息

0 项与 PPP1R8 相关的专利（医药）

登录后查看更多信息

265

项与 PPP1R8 相关的文献（医药）

2024-06-01·The FEBS Journal

DNA damage‐induced allosteric activation of protein phosphatase PP1:NIPP1 through Src kinase‐induced circularization of NIPP1

Article

作者: Van der Hoeven, Gerd ; Van Eynde, Aleyde ; Wu, Dan ; Claes, Zander ; Bollen, Mathieu

Protein phosphatase‐1 (PP1) complexed to nuclear inhibitor of PP1 (NIPP1) limits DNA repair through dephosphorylation of NIPP1‐recruited substrates. However, the PP1:NIPP1 holoenzyme is completely inactive under basal conditions, hinting at a DNA damage‐regulated activation mechanism. Here, we report that DNA damage caused the activation of PP1:NIPP1 after a time delay of several hours through phosphorylation of NIPP1 at the C‐terminal tyrosine 335 (Y335) by a Src‐family kinase. PP1:NIPP1 activation partially resulted from the dissociation of the C terminus of NIPP1 from the active site of PP1. In addition, the released Y335‐phosphorylated C terminus interacted with the N terminus of NIPP1 to enhance substrate recruitment by the flanking forkhead‐associated (FHA) domain. Constitutive activation of PP1:NIPP1 by knock‐in of a phospho‐mimicking (Y335E) NIPP1 mutant led to the hypo‐phosphorylation of FHA ligands and an accumulation of DNA double‐strand breaks. Our data indicate that PP1:NIPP1 activation through circularization of NIPP1 is a late response to DNA damage that contributes to the timely recovery from damage repair.

2024-02-01·Journal of Investigative Dermatology

Embryonic NIPP1 Depletion in Keratinocytes Triggers a Cell Cycle Arrest and Premature Senescence in Adult Mice

Article

作者: Lien, Wen-Hui ; Szekér, Kathelijne ; Van Eynde, Aleyde ; Azhir, Zahra ; Bollen, Mathieu ; Verbinnen, Iris ; Van der Hoeven, Gerd ; Ferreira, Mónica ; Jonkhout, Marloes C M ; Vanhessche, Tijs ; Withof, Fabienne

NIPP1 is a ubiquitously expressed regulatory subunit of PP1. Its embryonic deletion in keratinocytes causes chronic sterile skin inflammation, epidermal hyperproliferation, and resistance to mutagens in adult mice. To explore the primary effects of NIPP1 deletion, we first examined hair cycle progression of NIPP1 skin knockouts (SKOs). The entry of the first hair cycle in the SKOs was delayed owing to prolonged quiescence of hair follicle stem cells. In contrast, the entry of the second hair cycle in the SKOs was advanced as a result of precocious activation of hair follicle stem cells. The epidermis of SKOs progressively accumulated senescent cells, and this cell-fate switch was accelerated by DNA damage. Primary keratinocytes from SKO neonates and human NIPP1-depleted HaCaT keratinocytes failed to proliferate and showed an increase in the expression of cell cycle inhibitors (p21, p16/Ink4a, and/or p19/Arf) and senescence-associated-secretory-phenotype factors as well as in DNA damage (γH2AX and 53BP1). Our data demonstrate that the primary effect of NIPP1 deletion in keratinocytes is a cell cycle arrest and premature senescence that gradually progresse to chronic senescence and likely contribute to the decreased sensitivity of SKOs to mutagens.

2024-01-01·Bioinformatics and Biology Insights

Integration of Multi-Omics Data for the Classification of Glioma Types and Identification of Novel Biomarkers

Article

作者: Lopes, Marta B ; Bispo, Regina ; Vieira, Francisca G

Glioma is currently one of the most prevalent types of primary brain cancer. Given its high level of heterogeneity along with the complex biological molecular markers, many efforts have been made to accurately classify the type of glioma in each patient, which, in turn, is critical to improve early diagnosis and increase survival. Nonetheless, as a result of the fast-growing technological advances in high-throughput sequencing and evolving molecular understanding of glioma biology, its classification has been recently subject to significant alterations. In this study, we integrate multiple glioma omics modalities (including mRNA, DNA methylation, and miRNA) from The Cancer Genome Atlas (TCGA), while using the revised glioma reclassified labels, with a supervised method based on sparse canonical correlation analysis (DIABLO) to discriminate between glioma types. We were able to find a set of highly correlated features distinguishing glioblastoma from lower-grade gliomas (LGGs) that were mainly associated with the disruption of receptor tyrosine kinases signaling pathways and extracellular matrix organization and remodeling. Concurrently, the discrimination of the LGG types was characterized primarily by features involved in ubiquitination and DNA transcription processes. Furthermore, we could identify several novel glioma biomarkers likely helpful in both diagnosis and prognosis of the patients, including the genes PPP1R8, GPBP1L1, KIAA1614, C14orf23, CCDC77, BVES, EXD3, CD300A, and HEPN1. Collectively, this comprehensive approach not only allowed a highly accurate discrimination of the different TCGA glioma patients but also presented a step forward in advancing our comprehension of the underlying molecular mechanisms driving glioma heterogeneity. Ultimately, our study also revealed novel candidate biomarkers that might constitute potential therapeutic targets, marking a significant stride toward personalized and more effective treatment strategies for patients with glioma.